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Abstract
Background: Tiotropium is a once-daily, long-acting anticholinergic bronchodilator with the potential to alleviate airway
obstruction in cystic fibrosis. Our objective was to evaluate the efficacy and safety of 2.5 and 5 mg once-daily tiotropium
delivered via the Respimat Soft Mist Inhaler vs. placebo in people with cystic fibrosis.
Methods: This phase 2, 12-week, randomized, double-blind, placebo-controlled parallel-group study of tiotropium Respimat
as add-on to usual cystic fibrosis maintenance therapy included people with cystic fibrosis with pre-bronchodilator forced
expiratory volume in 1 second (FEV1) $25% predicted. Co-primary efficacy end points were change from baseline in
percent-predicted FEV1 area under the curve from 0 to 4 hours (FEV1 AUC0–4h), and trough FEV1 at the end of week 12.
Findings: A total of 510 subjects with cystic fibrosis aged 5–69 years were randomized. Both doses of tiotropium resulted in
significant improvement compared with placebo in the co-primary efficacy end points at the end of week 12 (change from
baseline in percent-predicted FEV1 AUC0–4h: 2.5 mg: 2.94%, 95% confidence interval 1.19–4.70, p = 0.001; 5 mg: 3.39%, 95%
confidence interval 1.67–5.12, p = 0.0001; in percent-predicted trough FEV1:2.5 mg: 2.24%, p = 0.2; 5 mg: 2.22%, p = 0.02).
There was a greater benefit with tiotropium 5 vs. 2.5 mg. No treatment-related adverse events or unexpected safety findings
were observed in patients taking tiotropium.
Conclusions: Tiotropium significantly improved lung function in people with cystic fibrosis. The improvement was greater
with the higher dose than the lower dose, with no difference in adverse events.
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Introduction
Respiratory disease is the major cause of death in people with
cystic fibrosis (CF), and new therapies addressing important
pathophysiologic aspects of CF are urgently needed [1]. Treat-
ments targeting airflow obstruction may provide clinical benefit to
people with CF. Current standard therapy includes antibiotics,
airway clearance techniques, dornase alfa, hypertonic saline, and
inhaled bronchodilators [2]. Approximately 80% of people with
CF use short- and/or long-acting bronchodilators, although their
place as long-term therapy is not clearly defined and there are no
bronchodilators with an approved indication for CF [3,4].
Bronchodilator agents improve pulmonary function and lessen
wheezing in many people with CF [4]. The similar effectiveness of
b2 agonists and anticholinergics suggests that a significant
proportion of airflow obstruction in CF is parasympathetically
mediated [5]. Anticholinergic treatment may therefore prove a
valuable add-on to current CF treatments.
A single dose of ipratropium bromide, a short-acting anticho-
linergic compound, has demonstrated lung function improvements
in people with CF [6]. However, the long-term effects of
maintenance therapy with ipratropium bromide have not been
studied in CF. Tiotropium bromide (hereafter referred to as
tiotropium), a long-acting anticholinergic compound delivered as
an aqueous solution using the Respimat Soft Mist Inhaler, has
consistently shown superior efficacy to ipratropium [7], and is well
tolerated in the treatment of chronic obstructive pulmonary
disease (COPD); these findings are consistent with those observed
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with the tiotropium 18 mg HandiHaler [8]. Tiotropium Respimat
therefore has the potential to alleviate airflow obstruction in
people with CF. Tiotropium Respimat was selected because the
inhaler and formulation are suitable for populations of all ages.
The inhaler is an active device that releases drug substance as an
aerosol; hence, no minimal inspiratory flow is required by the
patient. Suitability of the Respimat Soft Mist Inhaler was
demonstrated in children aged ,5 years using Respimat with a
valved holding chamber and facemask [9,10]. Results from a
phase 1 study (manuscript in press) showed that safety and
tolerability of tiotropium are acceptable when compared with
placebo in people with CF. Based on available data, tiotropium
delivered by Respimat was tested at doses of 2.5 and 5 mg in this
phase 2 study.
The primary objective was to evaluate the efficacy and safety of
12 weeks’ treatment with tiotropium Respimat 2.5 or 5 mg once
daily compared with placebo in people with CF. We hypothesized
that treatment with tiotropium for 12 weeks is more effective in
improving lung function compared with placebo, and that the
higher dose of tiotropium (5 mg) is more effective than the 2.5 mg
dose.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Study Design
This was a double-blind, placebo-controlled, multicenter,
multinational, parallel-group study to evaluate treatment with
two doses of tiotropium (2.5 and 5 mg once daily, two inhalations
at the same time of day) compared with placebo over 12 weeks
(ClinicalTrials.gov identifier: NCT00737100). The trial period was
from 23 September 2008 to 2 April 2010. The study was
conducted at 94 centers in Australia, Europe, Canada, and the
United States.
Ethical review was undertaken for each site/country by the local
institutional review board/independent ethics committee and
approval granted by the Competent Authority in each state.
Participants
Participants with documented CF had to be able to perform
spirometric maneuvers according to American Thoracic Society
(ATS) standards [11]. Patients of all ages were included, except in
Russia, where patients aged ,6 years were excluded. Subjects had
to have a screening pre-bronchodilator forced expiratory volume
in 1 second (FEV1) $25% of predicted values [12,13] and inhale
medication competently using the Respimat Soft Mist Inhaler.
Patients were trained using a placebo Respimat device. They were
to be clinically stable as defined by no evidence of acute
respiratory tract infection or pulmonary exacerbation requiring
use of antibiotics or oral corticosteroids within 4 weeks of
screening. Pre-bronchodilator FEV1 at week 0 or start of
treatment had to be within 15% of FEV1 at screening. All patients
continued to receive their standard-of-care treatment during the
study; tiotropium and placebo were considered add-on to usual
therapy. If patients were diagnosed with a pulmonary exacerba-
tion during the study period then this was recorded as an adverse
event (AE) or serious AE, but there was no requirement to
discontinue medication, and this decision was determined by the
patient and physician. If taking long-term medication, participants
had to agree to continue it throughout the study. Patients were
allowed to continue using short-acting b-agonists (SABAs) and
long-acting b-agonists (LABAs) if they were stabilized at least 4
weeks prior to randomization and throughout the study. Further-
more, patients taking SABAs and LABAs were required to have a
6-hour or 12-hour washout period, respectively, prior to all
spirometry measurements.
Daily inhaled antibiotic use was allowed if stabilized for at least
6 weeks prior to and throughout the study period. Cyclic therapies
(e.g., 4-week on/off tobramycin inhalation solution [TIS]) can
impact treatment outcomes in short-term early phase trials. Cycled
inhaled antibiotic use (e.g., TIS every other month) was allowed;
however, the start of treatment had to be scheduled 2 weeks after
the most recent TIS cycle and the last TIS cycle was to happen 2
weeks before the last treatment visit. This trial’s 12-week design
minimized the impact of cyclic medications by ensuring that
baseline and final assessments were scheduled at a similar time
point in the TIS cycle (i.e., both 2 weeks following completion of a
TIS cycle). In order to comply with a 4-week on/off TIS regimen,
the end-of-treatment visit may have been scheduled within 10–14
weeks after start of treatment to ensure baseline and end of study
assessments occurred at mid-point of an off month in participants
cycling TIS on alternate months. Physicians were advised to follow
similar timing for other cycled medication use as for TIS, although
this was not an official protocol procedure. Written informed
consent was obtained from each patient or the patient’s legal
representative. Exclusion criteria (see Protocol S1 and File S1)
included previous intolerance to tiotropium.
End Points
The co-primary end points for this trial were: i) the change from
baseline (30 min prior to administration of first tiotropium dose at
randomization; week 0) in percent-predicted FEV1 area under the
curve from time 0–4 hours (AUC0–4h) at the end of week 12; and
ii) the change from baseline (30 min prior to administration of first
tiotropium dose at randomization; week 0) in percent-predicted
trough FEV1 at the end of week 12. The secondary outcomes in
this study were changes from baseline in forced vital capacity
(FVC), residual volume/total lung capacity (RV/TLC), forced
expiratory flow (FEF) from 25% to 75% of vital capacity (FEF25–
75), Respiratory and Systemic Symptoms Questionnaire (RSSQ),
and health-related quality of life (Cystic Fibrosis Questionnaire-
Revised [CFQ-R]) at the end of week 12 [14]. AEs were also
recorded. To measure exposure to the study drug, all patients were
asked to return all dispensed Respimat inhalers.
Assessments
Pulmonary function tests (PFTs). The use of spirometers,
including daily calibration, met ATS/European Respiratory
Society criteria [15]. The qualifying PFTs (FEV1 and FVC) were
conducted at the screening visit. At weeks 0 and 12, PFTs were
performed pre-dose (–10 minutes prior to study drug inhalation),
at 30 minutes, and at 1, 2, 3, and 4 hours after inhalation of study
drug. FEV1 AUC0–4h was calculated using the trapezoidal rule
[16], divided by the duration (4 hours) reported in liters. Trough
FEV1 was defined as the FEV1 value performed at –30 minutes
prior to study drug inhalation. At weeks 4 and 8, PFTs were
performed 30 minutes prior to drug administration. During the
follow-up visit, after 30 days post-treatment (or at the time of
premature study discontinuation), a single PFT was performed.
Percent-predicted FEV1 was calculated using the reference
equations by Wang and colleagues [12] for pediatric/adolescents
(aged 6–18 years) and by Knudson and colleagues [13] for adults
(aged .18 years). RV/TLC measurements were performed as
described in File S1.
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Patient-reported outcomes. The proportion of patients
with at least one pulmonary exacerbation during the double-blind
period was analyzed using the RSSQ [17,18]. Health-related
quality of life was assessed as the change from baseline in CFQ-R
score [14]. Both methods are described in detail in File S1. For
patients aged 6–13 years and depending on the patient’s age and
reading ability, the CFQ-R was administered to the patient
directly, indirectly, or administered to their parent or caregiver.
No patient under the age of 6 years completed the CFQ-R.
Safety. Medical history was recorded at screening. All
patients were reviewed at screening and baseline entry into the
study and at 2, 4, 8, and 12 weeks of therapy, and then at 30 days’
post-treatment. Health status of patients who withdrew prema-
turely from the treatment period was followed up until their
predicted study completion date. At each visit, all AEs and serious
AEs, regardless of causality, were recorded.
Statistical Analyses
The primary analyses were performed in all randomized
patients who received at least one dose of study drug and had
both baseline and at least one post-dose PFT measurement at or
before 12 weeks for either co-primary efficacy variable. Mean
change from baseline in the co-primary efficacy variables (FEV1
AUC0–4h and trough FEV1) was analyzed using a restricted
maximum likelihood–based mixed-effect model with repeated
measures (MMRM). To model the within-patient errors, an
unstructured covariance matrix was used. Analyses were imple-
mented using Statistical Analysis System software version 8.2 (SAS
Institute Inc., Cary, NC, USA). The primary comparisons were
between treatments after 12 weeks. The first co-primary end point,
FEV1 AUC0–4h, was also stratified by age group. The age variable
was dichotomized into patients aged 12 years and older and
patients aged 11 years and younger, and was included in the
model as a fixed effect. Other terms in the model were
‘‘treatment,’’ ‘‘visit,’’ ‘‘treatment-by-visit interaction,’’ ‘‘baseline’’
and ‘‘baseline-by-visit interaction,’’ and ‘‘random effect of center.’’
Prespecified subgroup analyses for both primary end points
included age group and baseline LABA use. The subgroup
analyses were performed by adding subgroup, treatment-by
subgroup, visit-by-subgroup, and treatment-by-visit-by subgroup
interaction into the primary model.
All secondary end points on additional PFT parameters were
analyzed as in the primary analysis, using the same MMRM
model. For exacerbation analyses, Mantel-Haenszel test was
adjusted for age group; treatment and age group were covariates
for logistic regression analysis. The duration of pulmonary
exacerbation was calculated based on the AE listings. Safety end
points were summarized descriptively.
Data considered to be missing at random were not imputed, but
handled in the analysis via the use of the MMRM model; only
data that could be considered not missing at random were
imputed. Randomly missing data with no subsequent non-missing
values for that visit were imputed using the last observation carried
forward technique (FEV1, FVC, and FEF25–75 measurements).
In order to detect a difference of five units in the percentage
change from baseline in FEV1 values between tiotropium and
placebo with 80% power at a two-sided significance level of 5%, a
minimum of 465 patients in the full analysis set were required
(155 in each treatment group). Based on a previous study [19], an
approximate estimate of the expected standard deviation for FEV1
percent-predicted value at screening was used (15.66). In this
study, the ratio of adult to pediatric patients was approximately
2:1.
A detailed description of blinding and randomization and
handling of missing data can be found in File S1.
Results
The study flow for this trial is summarized in Figure 1 [20].
Demographics and Other Baseline Characteristics
Of 620 recruited patients, a total of 510 patients (54% male)
were randomized and treated (placebo, n= 168; tiotropium
2.5 mg, n= 166; tiotropium 5 mg, n= 176). Mean (SD) age was
20.9 (11.6) years (range, 5–69 years) and 27.1% were aged #11
years (range, 5–11 years). There were no clinically relevant
differences between treatment groups (overall or by age group) in
any demographic or baseline characteristic (Table 1).
Co-primary Efficacy End Points
For percent-predicted FEV1 AUC0–4h at the end of week 12,
adjusted changes (improvements) from baseline were greater for
both doses of tiotropium compared with placebo (tiotropium
2.5 mg: 1.20%; tiotropium 5 mg: 1.65%; placebo: –1.74%.
Tiotropium 2.5 mg difference from placebo [95% CI]: 2.94%
[1.19, 4.70], p= 0.001; tiotropium 5 mg difference from placebo
[95% CI]: 3.39% [1.67, 5.12], p = 0.0001) (Fig. 2). The adjusted
mean change was larger in the tiotropium 5 mg group than in the
tiotropium 2.5 mg group (Fig. 2). The additional bronchodilator
efficacy observed in the tiotropium 5 mg group was driven by the
results obtained in patients younger than 12 years (Table 2). Both
tiotropium dose groups had estimated mean changes (improve-
ments), measured in liters at the end of week 12 (Table 2), that
were statistically significantly greater than that of placebo.
Adjusted changes (improvements) from baseline in percent-
predicted trough FEV1 (at end of week 12) were greater for both
doses of tiotropium compared with placebo (tiotropium 2.5 mg:
0.81%; tiotropium 5 mg: 0.78%; placebo: –1.44%. Tiotropium
2.5 mg difference from placebo [95% CI]: 2.24% [0.38, 4.11],
p = 0.02; tiotropium 5 mg difference from placebo [95% CI]:
2.22% [0.38, 4.06], p = 0.02; Table 3). The mean adjusted change
was similar between the tiotropium 2.5 mg and 5 mg groups and
was not affected by age.
Other Lung Function Measures
Both the 2.5 and 5 mg doses of tiotropium had adjusted mean
improvements from baseline in percent-predicted FVC AUC0–4h
response that were greater than placebo (tiotropium 2.5 mg:
0.53%; tiotropium 5 mg: 1.81%; placebo: –1.30%. Tiotropium
2.5 mg difference from placebo [95% CI]: 1.83% [–0.19, 3.86],
p = 0.08; tiotropium 5 mg difference from placebo [95% CI]:
3.12% [1.12, 5.12], p = 0.002). The mean adjusted change was
greater for tiotropium 5 than 2.5 mg and was only statistically
significant for the tiotropium 5 mg group. The observed improve-
ment for FVC AUC0–4h in the tiotropium 5 mg group was largely
driven by results in patients aged #11 years (described in detail in
File S1).
Both doses of tiotropium had estimated adjusted mean
improvements in percent-predicted trough FVC response that
were greater than placebo, but not statistically significant
(tiotropium 2.5 mg: 0.47%; tiotropium 5 mg: 0.81%; placebo: –
0.39%. Tiotropium 2.5 mg difference from placebo [95% CI]:
0.85% [–1.08, 2.79], p = 0.4; tiotropium 5 mg difference from
placebo [95% CI]: 1.19% [–0.72, 3.11], p = 0.2). FEF25–75 results
were consistent with these results; static lung hyperinflation as
measured by RV/TLC showed no difference between dose groups
(described in detail in File S1).
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Exposure
Overall exposure to study drug was acceptable, with a mean
(SD) duration of treatment of 85.6 days (12.1); 87.5% of patients
(446/510) took their study drug between .10 and #14 weeks.
Approximately 9% of patients (47/510) took their study drug for
$14 weeks.
Pulmonary Exacerbation as Assessed by RSSQ and
Health-Related Quality of Life by CFQ-R
The proportions of patients who had at least one pulmonary
exacerbation as determined by the RSSQ and intravenous
antibiotic use were lower in the tiotropium 2.5 mg (7.8%) and
5 mg (6.9%) groups compared with the placebo group (9.6%; not
statistically significant; p = 0.9 and p= 0.6 vs. placebo for
tiotropium 2.5 mg and 5 mg respectively). Except for one
pulmonary exacerbation in each treatment group, all events
occurred in patients aged $12 years. The CFQ-R scores did not
differ from baseline throughout the study period and no difference
between the treatment groups was observed (additional results
detailed in File S1).
Figure 1. Flow diagram of participant recruitment and randomization [20].
doi:10.1371/journal.pone.0106195.g001
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Subgroup Analysis
Differences in response to tiotropium by baseline LABA were
explored by a prespecified subgroup analysis. In patients who used
LABA at baseline, a larger difference compared with placebo
(n = 64) was observed for the tiotropium 5 mg group (n= 56;
5.30% difference; 3.09% vs. –2.21%; 95% CI, 2.44–8.2;
p = 0.0003) than for the tiotropium 2.5 mg (n= 60; 1.79%
difference; –0.43% vs. –2.21%; 95% CI, –1.03 to –4.61;
p = 0.2). In patients who did not use LABA at baseline, similar
differences compared with placebo (n= 99) were observed for both
tiotropium groups (tiotropium 2.5 mg: n= 98, 3.63% difference,
2.19% vs. –1.44%, 95% CI, 1.40–5.86, p = 0.002; tiotropium
5 mg: n= 113, 2.37% difference, 0.93% vs. –1.44%, 95% CI,
0.22–4.53, p = 0.03).
Adverse Events
The majority of patients (82.9%) reported one or more AE
during the study. Most were mild to moderate in intensity and
were primarily of respiratory nature; the most common AEs
(defined as AE with an incidence .5% in any treatment group)
were cough, exacerbation of CF, pyrexia, nasopharyngitis, and
headache (Table 4). All deaths (two in the placebo group and one
in the tiotropium 2.5 mg group) were due to exacerbation and/or
complications of CF. An overall summary of AEs is provided in
Table 1. Patient demographics and characteristics of the study population at baseline.
Placebo Tiotropium 2.5 mg Tiotropium 5 mg Total
No. of patients 168 166 176 510
Male sex, n (%) 96 (57.1) 85 (51.2) 94 (53.4) 275 (53.9)
Age, years (mean, SD) 20.4 (11.6) 21.5 (12.0) 20.7 (11.3) 20.9 (11.6)
Age group, n (%)
#11 years 44 (26.2) 42 (25.3) 52 (29.5) 138 (27.1)
$12 years 124 (73.8) 124 (74.7) 124 (70.5) 372 (72.9)
Percent-predicted FEV1, (mean, SD) 76.6 (23.8) 75.4 (26.7) 75.9 (22.6) 76.0 (24.3)
#11 years 94.9 (16.7) 98.8 (16.1) 90.3 (15.5) 94.3 (16.3)
$12 years 70.1 (22.5) 67.5 (24.9) 69.9 (22.4) 69.2 (23.3)
BMI, kg/m2 (mean, SD) 20.3 (4.4) 19.9 (4.0) 20.0 (4.1) 20.1 (4.2)
Baseline* concomitant pulmonary medications, n (%) 129 (76.8) 121 (72.9) 128 (72.7) 378 (74.1)
SABA 103 (61.3) 90 (54.2) 111 (63.1) 304 (59.6)
LABA 67 (39.9) 63 (38.0) 58 (33.0) 188 (36.9)
*Baseline includes all medications used on at least 1 day between informed consent and randomization (inclusive) and on at least 1 day between randomization and
the first day of randomized drug intake (inclusive). BMI, body mass index; FEV1, forced expiratory volume in 1 second; LABA, long-acting b-agonist; SABA, short-acting b-
agonist; SD, standard deviation.
doi:10.1371/journal.pone.0106195.t001
Figure 2. Adjusted mean FEV1 AUC0–4h (percent-predicted± SE) change from baseline (full analysis set). AUC0–4h, area under the curve
from 0 to 4 hours; FEV1, forced expiratory volume in 1 second.
doi:10.1371/journal.pone.0106195.g002
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Table 5 (and in File S1). Frequency of AEs was similar in all
treatment arms and there was no evidence of a treatment
relationship for any AE category; small differences between
treatment groups were considered consequent to variability related
to the overall small number of events.
Table 2. Adjusted mean (SE) changes from baseline in FEV1 AUC0–4h overall and in patients (aged #11 years and $12 years)
treated with tiotropium (2.5 or 5 mg) or placebo after 12 weeks*.
Age group Treatment Difference from placebo
Treatment Mean (SE) Mean (SE) p value 95% CI
Overall, % predicted
Placebo (n = 163) –1.74 (0.65)
Tiotropium 2.5 mg (n = 158) 1.20 (0.66) 2.94 (0.89) 0.0010 1.19–4.70
Tiotropium 5 mg (n = 169) 1.65 (0.63) 3.39 (0.88) 0.0001 1.67–5.12
Overall, L
Placebo (n = 163) 20.07 (0.02)
Tiotropium 2.5 mg (n = 158) 0.02 (0.02) 0.09 (0.03) 0.0004 0.04–0.14
Tiotropium 5 mg (n = 169) 0.03 (0.02) 0.09 (0.02) 0.0002 0.05–0.14
#11 years, % predicted
Placebo (n = 43) –0.32 (1.26)
Tiotropium 2.5 mg (n = 42) 2.01 (1.29) 2.33 (1.74) 0.1801 –1.08 to 5.75
Tiotropium 5 mg (n = 50) 3.57 (1.16) 3.89 (1.67) 0.0199 0.62–7.17
$12 years, % predicted
Placebo (n = 120) –2.55 (0.75)
Tiotropium 2.5 mg (n = 116) 0.57 (0.76) 3.12 (1.04) 0.0028 1.08–5.17
Tiotropium 5 mg (n = 119) 0.55 (0.75) 3.11 (1.03) 0.0028 1.08–5.14
*Analysis of the full analysis set study group based on mixed-effect model with repeated measures model using unstructured covariance matrix.
AUC0–4h, area under the curve from 0 to 4 hours; CI, confidence interval; FEV1, forced expiratory volume in 1 second; SE, standard error.
doi:10.1371/journal.pone.0106195.t002
Table 3. Adjusted mean (SE) changes from baseline in overall trough FEV1 response and in patients (aged #11 years and $12
years) treated with tiotropium (2.5 or 5 mg) compared with placebo after 12 weeks*.
Treatment Difference from placebo
Treatment Mean change (SE) Mean change (SE) p value 95% CI
Overall, % predicted
Placebo (n = 163) –1.44 (0.71)
Tiotropium 2.5 mg (n = 158) 0.81 (0.71) 2.24 (0.95) 0.0184 0.38–4.11
Tiotropium 5 mg (n = 169) 0.78 (0.69) 2.22 (0.93) 0.0179 0.38–4.06
Overall, L
Placebo (n = 163) 20.06 (0.02)
Tiotropium 2.5 mg (n = 158) 20.00 (0.02) 0.06 (0.03) 0.0330 0.00–0.11
Tiotropium 5 mg (n = 169) 20.00 (0.02) 0.06 (0.03) 0.0281 0.01–0.11
#11 years, % predicted
Placebo (n = 43) 20.83 (1.35)
Tiotropium 2.5 mg (n = 42) 2.71 (1.38) 3.54 (1.86) 0.0577 20.12 to 7.19
Tiotropium 5 mg (n = 50) 1.85 (1.24) 2.68 (1.78) 0.1322 20.81 to 6.18
$12 years, % predicted
Placebo (n = 120) 22.14 (0.80)
Tiotropium 2.5 mg (n = 116) 20.38 (0.81) 1.76 (1.11) 0.1128 20.42 to 3.94
Tiotropium 5 mg (n = 119) 20.11 (0.80) 2.03 (1.10) 0.0668 20.14 to 4.20
*Analysis of the full analysis set study group based on mixed-effect model with repeated measures model using unstructured covariance matrix.
CI, confidence interval; FEV1, forced expiratory volume in 1 second; SE, standard error.
doi:10.1371/journal.pone.0106195.t003
Phase 2 Trial of Tiotropium in Cystic Fibrosis
PLOS ONE | www.plosone.org 6 September 2014 | Volume 9 | Issue 9 | e106195
Discussion
This is the first study to evaluate and provide evidence for the
safety and efficacy of tiotropium in people with CF. Both doses of
tiotropium resulted in statistically significant improvements
compared with placebo in the co-primary efficacy end points of
FEV1 AUC0–4h and trough FEV1. Similarly, results for FEV1
AUC0–4h in liters and for FVC support the findings of the primary
end points. Interestingly, a treatment benefit for respiratory
symptoms (based on RSSQ) or health-related quality of life (based
on CFQ-R) was not observed with either dose of tiotropium. Both
doses of tiotropium were safe and well tolerated. The age subgroup
analyses performed in our study demonstrate that tiotropium 5 mg
is effective, with a favorable safety profile in children as well as in
adults. The results from this study led to a phase 3 trial being
performed using the 5 mg tiotropium dose [21].
Table 4. Summary of adverse events that occurred in .5% of patients in any treatment group (treated set).
Placebo Tiotropium 2.5 mg Tiotropium 5 mg Total
No. of patients, n 168 166 176 510
Cough, n (%) 34 (20.2) 35 (21.1) 46 (26.1) 115 (22.5)
Cystic fibrosis*, n (%) 17 (10.1) 23 (13.9) 25 (14.2) 65 (12.7)
Pyrexia, n (%) 17 (10.1) 9 (5.4) 18 (10.2) 44 (8.6)
Nasopharyngitis, n (%) 14 (8.3) 11 (6.6) 14 (8.0) 39 (7.6)
Headache, n (%) 18 (10.7) 7 (4.2) 14 (8.0) 39 (7.6)
Sputum increased 8 (4.8) 12 (7.2) 13 (7.4) 33 (6.5)
Abdominal pain 10 (6.0) 13 (7.8) 9 (5.1) 32 (6.3)
Hemoptysis 7 (4.2) 13 (7.8) 12 (6.8) 32 (6.3)
Oropharyngeal pain 13 (7.7) 5 (3.0) 11 (6.3) 29 (5.7)
Bronchitis 9 (5.4) 6 (3.6) 10 (5.7) 25 (4.9)
Upper respiratory tract infection 6 (3.6) 8 (4.8) 11 (6.3) 25 (4.9)
Rhinorrhea 9 (5.4) 6 (3.6) 9 (5.1) 24 (4.7)
Dyspnea 9 (5.4) 8 (4.8) 6 (3.4) 23 (4.5)
Nasal congestion 4 (2.4) 9 (5.4) 10 (5.7) 23 (4.5)
Sinusitis 6 (3.6) 3 (1.8) 9 (5.1) 18 (3.5)
Arthralgia 9 (5.4) 5 (3.0) 4 (2.3) 18 (3.5)
*The preferred adverse event term used for ‘‘CF exacerbation’’ was ‘‘cystic fibrosis.’’
A patient may have been counted in more than one preferred term. Percentages were calculated using the total number of patients per treatment as the denominator.
Medical Dictionary for Regulatory Activities (MedDRA) version used for reporting: 13.0.
doi:10.1371/journal.pone.0106195.t004
Table 5. Overall summary of adverse events (treated set).
Placebo Tiotropium 2.5 mg Tiotropium 5 mg Total
No. of patients, n 168 166 176 510
Patients with any AE, n (%) 139 (82.7) 139 (83.7) 145 (82.4) 423 (82.9)
Patients with an SAE, n (%) 7 (4.2) 13 (7.8) 10 (5.7) 30 (5.9)
Patients with a study drug-related AE*, n (%) 14 (8.3) 15 (9.0) 18 (10.2) 47 (9.2)
Patients with other significant AE{, n (%) 3 (1.8) 2 (1.2) 3 (1.7) 8 (1.6)
Patients with AE leading to discontinuation of study drug, n (%) 6 (3.6) 6 (3.6) 3 (1.7) 15 (2.9)
Patients with SAEs, n (%) 21 (12.5) 28 (16.9) 21 (11?9) 70 (13.7)
Fatal, n 2 1 0 3
Immediately life-threatening, n 1 0 0 1
Disability/incapacity, n 0 0 1 1
Required hospitalization, n 21 28 21 70
Prolonged hospitalization, n 1 1 0 2
Congenital anomaly, n 0 0 0 0
Other, n 0 0 0 0
*As assessed by the study investigators. {As defined by International Conference on Harmonisation (ICH) E3 guidelines.
A patient may have been counted in more than one seriousness criterion. AE, adverse event; SAE, serious AE.
doi:10.1371/journal.pone.0106195.t005
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This study has a number of challenges in design, relating in
particular to the use of cycled inhaled antibiotics. Study design was
such that measurements were made on the off phase of inhaled
antibiotic treatment for those on such treatment. The study was
not sufficiently long to confidently determine the presence of any
significant changes in symptoms or pulmonary exacerbations. The
effects seen in the study should therefore be interpreted as
demonstrating short- to medium-term effect of bronchodilator
therapy by tiotropium. The study was, however, sufficiently
powered to detect a meaningful change in FEV1.
Despite widespread use, there is limited evidence supporting the
use of bronchodilators in CF. A recent systematic review
concluded that short-acting anticholinergics had no consistent
effect on lung function tests in people with CF [22]. Efficacy of the
LABA salmeterol in people with CF has only been investigated in
several short-term (,1 week duration) clinical trials [23,24].
Results from one trial of longer-term use (24 weeks) showed
improvement in FEV1 in people with CF compared with
treatment with salbutamol; however, no significant effect of
salmeterol on other spirometric indices were detected in this trial,
and therefore the clinical relevance of these results is debatable
[25,22].
The highest tiotropium dose tested in this study, 5 mg daily,
resulted in lung function improvement that was numerically above
that observed for 2.5 mg. The study was not powered for
differences between doses and no statistical comparison was
performed; however, the effect of the 5 mg dose was about 15%
greater than that of the 2.5 mg dose (percent-predicted FEV1
AUC0–4h) and the effect of the higher dose was more consistent
across visits. Based on a numerically superior efficacy and a similar
AE profile of both doses, 5 mg appeared to be the preferred dose
for subsequent clinical development of tiotropium in people with
CF. Longer term studies are required to evaluate the effect of
tiotropium on symptoms.
Tiotropium Respimat 5 mg is also the approved dose for COPD
patients, in whom evidence for improvements in lung function,
exercise tolerance, and health-related quality of life, as well as
reduction in the frequency of exacerbations, exists [26,27,28].
Effect sizes of lung function improvements for treatments used
in CF patients vary widely [22] and it is difficult to compare the
magnitude of improvement between different inhaled therapies
such as mannitol [29,30], hypertonic saline [31], and TIS [32], as
different variables are used (absolute change in FEV1 from
baseline vs. relative change). Currently, people with CF are
recommended complex, time-intensive daily therapies that are
often difficult to sustain over the long term, and the addition of
new therapies usually increases that burden [33]. Drug delivery
using the Respimat Soft Mist Inhaler is fast, easier than the more
traditional metered-dose inhaler, and does not require a power
source [34]. Furthermore, because it is effective over 24 hours,
tiotropium only requires once-daily inhalation and therefore may
ease the burden of the number of daily medications required in
CF, contributing to improved compliance.
Conclusion
This study provides evidence of the efficacy and safety of
inhaled tiotropium delivered by the Respimat Soft Mist Inhaler in
people with CF and supports proceeding to further investigations
in phase 3.
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